When you walk into Grass Roots Medicinal in Squamish you only get access to the waiting room. There, a small counter offers bongs and other glassware for sale. All the good stuff — the grass the store gets its name from — is locked up behind a second door, out of reach. To get there, […]

by

Botanix Pharmaceuticals (ASX:BOT) has received approval to conduct the first clinical study of synthetic cannabidiol for acne using the company’s BTX 1503 product. The approval was granted by the Human Research Ethics Committee (HREC) of the Queensland Institute for Medical Research. Botanix’s shares were last trading 10% higher intra-day, at $0.064. The recruitment of volunteers […]

by

GW Pharmaceuticals Announces Epidiolex(R) Receives Orphan Drug Designation from the European Medicines Agency for the Treatment of Lennox-Gastaut Syndrome LONDON, March 29, 2017 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq:GWPH) (“GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics… read more at: https://www.newcannabisventures.com/gw-pharmas-epidiolex-receives-orphan-drug-designation-in-europe/

by

LONDON, March 29, 2017 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq:GWPH) (“GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation to GW’s investigational product Epidiolex® (cannabidiol or CBD) […]

by

According to a new report by Arcview Market Research, the legal cannabis consumer spending across North America, grew 34 percent to $6.7 billion and can be expected to grow at a 27 percent compound annual growth rate of (CAGR) over the next five years, from $6.7 billion in 2016, to $22.6 billion in 2021. This […]

by

NEW YORK, March 27, 2017 /PRNewswire/ — FinancialBuzz.com News Commentary  According to a new report by Arcview Market Research, the legal cannabis consumer spending across North America, grew 34 percent to $6.7 billion and can be expected to grow at a 27 percent compound annual growth rate of (CAGR) over the next five years, from […]

by

Presented Phase 1 Data on ZYN002 CBD Gel at the 70th Annual Meeting of the American Epilepsy Society  At the 70th Annual Meeting of the American Epilepsy Society held in December, results from a Phase 1 double-blind, placebo-controlled single ascending dose study involving 32 healthy adults were presented in two  posters entitled, “Neuropsychological Effects of […]

by

StockTwits    Before the market open his morning, Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) announced that it had completed enrollment for two Phase 2 trials evaluating its synthetic transdermal cannabidiol (CBD) – a marijuana-derived, non-psychoactive topical gel it’s been developing. The first study will be assessing the drug, called ZYN002, in refractory focal seizures – and the second […]

by

The cannabis industry has swiftly turned into a multi-billion dollar opportunity. In the United States, this market’s massive growth potential is being recognized as new states legalize marijuana for medical or recreational use. Industry experts forecast the U.S. cannabis market rounding $7 billion in 2016, while the annual sale of state-legal cannabis products is forecast […]

by

StockTwits    On Wednesday, Intec Pharma Ltd (NASDAQ:NTEC) announced that it had initiated a Phase 1 clinical program to evaluate its delivery system for marijuana-based therapeutics. The product, which is called the “Accordion Pill,” is a proprietary delivery system for the company’s marijuana-based therapeutics, which are being developed for a number of indications – including pain […]

by

Opko Health Inc. (OPK) announced that it secured orphan drug designation from the U.S. Food And Drug Administration (FDA) for CUR-1916, its novel therapy for treating Dravet Syndrome, a genetic neurological disorder. (See also, Opko Health Outlines 2017 Plans.) The coveted designation offers many benefits and incentives to drug makers, including expedited FDA approval, no […]

by

Say the word “cancer” and most people feel one thing: fear. That’s because, now more than ever, cancer seems to strike across such a broad range of categories — young, old, thin, fat, athletic, stationary and everything in between. With cancer’s prevalence, so too are its “cures,” many of which are wishy-washy in the name […]

by